Scienmag
FEBRUARY 13, 2021
Credit: City of Hope In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer – findings expected to change medical practice. These findings will be presented at ASCO’s virtual 2021 Genitourinary Cancers Symposium […].
Drug Patent Watch
FEBRUARY 13, 2021
Annual Drug Patent Expirations for ZIOPTAN Zioptan is a drug marketed by Akorn and is included in one NDA. It is available from one supplier. There are two patents protecting…. The post New patent for AKORN drug ZIOPTAN appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioTech 365
FEBRUARY 13, 2021
Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx – QuantuMDx has developed Q-POC™ – a rapid, PCR diagnostic device for coronavirus testing at the point of … Continue reading →
Drug Patent Watch
FEBRUARY 13, 2021
Annual Drug Patent Expirations for JUBLIA Jublia is a drug marketed by Bausch and is included in one NDA. It is available from one supplier. There are fourteen patents protecting…. The post New patent for Bausch drug JUBLIA appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
BioTech 365
FEBRUARY 13, 2021
Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET … Continue reading →
Drug Patent Watch
FEBRUARY 13, 2021
Annual Drug Patent Expirations for GALAFOLD Galafold is a drug marketed by Amicus Theraps Us and is included in one NDA. There are twenty-one patents protecting this drug. This drug…. The post New patent for Amicus Theraps drug GALAFOLD appeared first on DrugPatentWatch - Make Better Decisions.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Drug Patent Watch
FEBRUARY 13, 2021
This chart shows the pharmaceutical companies with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.
BioTech 365
FEBRUARY 13, 2021
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc.
Scienmag
FEBRUARY 13, 2021
Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer The combination also improved progression-free survival and overall response rate BOSTON – Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients […].
Expert insights. Personalized for you.
98 
Let's personalize your content